Last $72.00 USD
Change Today -0.11 / -0.15%
Volume 6.7M
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
$73.02
Previous Close
$72.11
Day High
$73.47
Day Low
$71.58
52 Week High
12/11/14 - $75.10
52 Week Low
02/10/14 - $52.29
Market Cap
80.2B
Average Volume 10 Days
4.4M
EPS TTM
$2.48
Shares Outstanding
1.1B
EX-Date
02/11/15
P/E TM
29.0x
Dividend
$2.00
Dividend Yield
2.72%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 01/30/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Eli Lilly and Company announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, total revenue was $5,121.3 million compared to $5,808.8 million a year ago. Operating income was $376.4 million compared to $900.8 million a year ago. Income before income taxes was $513.6 million compared to $909.9 million a year ago. Net income was $428.5 million or $0.40 diluted per share compared to $727.5 million or $0.67 diluted per share a year ago. Non-GAAP adjusted total revenue was $5,121.3 million compared to $5,808.8 million a year ago. Non-GAAP adjusted net income was $797.6 million or $0.75 diluted per share compared to $796.9 million or $0.74 diluted per share a year ago. The revenue decline was comprised of 9% due to lower volume and 4% due to the unfavorable impact of foreign exchange rates, partially offset 1% due to higher prices. For the year, total revenue was $19,615.6 million compared to $23,113.1 million a year ago. Operating income was $2,659.8 million compared to $5,370.4 million a year ago. Income before income taxes was $3,000.3 million compared to $5,889.3 million a year ago. Net income was $2,390.5 million or $2.23 diluted per share compared to $4,684.8 million or $4.32 diluted per share a year ago. Non-GAAP adjusted total revenue was $19,615.6 million compared to $23,113.1 million a year ago. Non-GAAP adjusted net income was $2,987.6 million or $2.78 diluted per share compared to $4,502.6 million or $4.15 diluted per share a year ago. The revenue decrease was comprised of 13% due to volume, 2% due to the unfavorable impact of foreign exchange rates, and 1% due to lower prices. The company has revised certain elements of its 2015 financial guidance solely to reflect the recent strengthening of the USD compared with several other currencies. The company still expects full-year 2015 earnings per share to be in the range of $2.40 to $2.50 on a reported basis. On a non-GAAP basis, full year 2015 earnings per share are still expected to be in the range of $3.10 to $3.20. The company anticipates 2015 revenue of between $19.5 billion and $20.0 billion. The acquisition of Novartis Animal Health is expected to add significant revenue. Research and development expenses are expected to be in the range of $4.7 billion to $4.9 billion reflecting an expected increase in Phase III trial expenses and the inclusion of Novartis Animal Health. The 2015 tax rate is still expected to be approximately 18.5% on a reported basis and 21.5% on a non-GAAP basis, assuming a full-year 2015 benefit of the R&D tax credit and other tax provisions up for extension. Capital expenditures are still expected to be approximately $1.3 billion.

Eli Lilly to Invest USD 12 Million in Increasing Production at Spanish Facility

Eli Lilly has chosen its Spanish subsidiary to take over some of the company's production capacity that would be lost after restructuring of its manufacturing facilities in Indianapolis (US). Therefore, the company is planning a new investment of more than EUR 11 million (USD 12 million) in order to increase production capacity in its facility in Madrid. Eli Lilly has taken a cost-effective decision to move some its US production in the Spanish market taking into account that production costs and salaries are noticeably lower in Spain.

Eli Lilly and Company and Merck Enter Collaboration Agreement

Merck and Eli Lilly and Company announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. Merck will conduct a phase II study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling. Lilly will conduct a multiple-arm Phase I/II study examining the combination of ramucirumab with pembrolizumab in multiple tumours. This study is anticipated to begin in 2015. Lilly will conduct a phase I/II study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $72.00 USD -0.11

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.76 USD -0.50
AbbVie Inc $60.35 USD -2.77
Amgen Inc $152.26 USD -4.11
AstraZeneca PLC 4,743 GBp -18.50
Teva Pharmaceutical Industries Ltd $56.86 USD -0.70
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 28.8x
Price/Sales 3.8x
Price/Book 4.4x
Price/Cash Flow 29.8x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.